NetScientific nets biotech stalwart

NetScientific nets biotech stalwart

12.05.2015 - London-based Biomedical and healthcare technology group NetScientific has announced the appointment of biotech stalwart François Regis Martelet as its new CEO and Board Director. He will join the Group on 8 June taking over from Sir Richard Sykes, who will revert to his position as Non-Executive Chairman.

From April 2013 – October 2014, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. Prior to SVP, he was CEO at Topotarget A/S, a publicly traded European biotech company specialising in oncology therapeutics, which François successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit. He also headed US-based biotech Avax Technologies Inc. as CEO, which focuses on therapeutic oncology vaccines. During François’ rich and long career, he has also held several senior commercial positions at Merck & Co, Inc, Novartis Pharma, Schering-Plough and Eli Lily. François holds a PhD in Medicine and a Masters degree in Business.

16.10.2014 Biochemistry professor Michel Bouvier has been appointed as new chairman of the Scientific Advisory Board at Strasbourg-based Domain Therapeutics.

© Domain Therapeutics

As professor in the Department of Biochemistry and Molecular Medicine at the University of Montreal, and also CEO of the Institute for Research in Immunology and Cancer (IRIC), Michel Bouvier brings a wealth of experience and knowledge to the board at Domain Therapeutics. The biopharmaceutical company specialises in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs) and will assemble a team of experts in drug discovery and development. In the coming months, Bouvier will work closely with the Domain Therapeutics’ management team to assemble a group of academic and industrial peers.

08.10.2014 Karolinska Development has announced the appointment of its new CEO. Oncology expert Bruno Lucidi has been appointed CEO of the wholly owned subsidiary KDev Oncology and the portfolio companies Aprea and Akinion Pharmaceuticals.

© Karolinska Development

Lucidi has extensive international experience in the pharmaceutical industry. Before becoming CEO at Karolinska Development, Bruno previously held positions as CEO of Idenix and Chairman of Pharmasset, where he contributed to maturing the companies to a level that eventually resulted in both companies being acquired by multinational pharmaceutical companies. Lucidi has also held senior positions within Bristol-Myers Squibb and Global Head of Oncology Strategy, at Johnson & Johnson as Global Head of Oncology Strategy from Drug Discovery to Market and at GlaxoSmithKline.

29.09.2014 After serving on the board since January 2014 at Abcam plc, Alan Hirzel has been appointed as the new CEO of Abcam – a leading provider of innovative protein research tools and services.

© Abcam plc

Alan Hirzel will succeed Jonathan Milner, the long-serving Chief Executive and co-Founder of Abcam. Hirzel brings an impressive combination of a strong scientific background, global business and leadership experience, and consumer knowledge. Hirzel takes on the role of CEO after having spent the last year as Chief Marketing Officer. As CMO he was responsible for the company’s branding, product portfolio and online consumer offering, and worked closely with Jonathan Milner to develop Abcam’s strategic vision.

26.09.2014 Drug discovery and development company Novimmune SA has named Adrian Mills as the company’s new CBO and member of the Executive Committee.

© Novimmune SA

Adrian Mills will be leading Novimmune’s commercial development activities as well as business development. With over 20 years of experience as a pharmaceutical executive, he has a particular focus on the commercialisation of orphan drugs. Mills joins Novimmune after 13 years at GlaxoSmithKline (GSK), where he held several strategic and operational positions in Europe and SE Asia. Most recently he was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Mills worked in management consulting and investment banking in the life sciences sector.

23.09.2014 Reneuron Group, a leading UK-based stem cell therapy company, has appointed Olav Hellebø as their new Chief Executive Officer.

© Reneuron

A highly experienced pharmaceutical executive, Hellebø has broad commercial experience gained at both major pharmaceutical and small biotechnology companies in the fields of clinical development, commercialism and marketing of new therapeutics. Before taking on the role of CEO at ReNeuron, Hellebø held the position of CEO at Clavis Pharma ASA, a Norwegian company specialising in oncology. Prior to Clavis, Hellebø was at the helm of UCB Pharma and head of the UK operations of Novartis. Hellebø began his pharmaceutical career in 1992 at Schering-Plough, where he held senior commercial roles in Europe and the US.

22.09.2014 Frank Ubags has joined Cevec Pharmaceuticals to lead its new CMO initiative.

© Cevec Pharmaceuticals

He will replace Rainer Lichtenberger as Managing Director and will channel the extension of Cevec’s offerings to customers and production of up to Phase II cGMP material in CAP cells. Ubags has served more than 35 years in senior positions at firms that include Rhein Biotech, Kiadis Pharma and Scil Proteins. Ubags managed Scil Proteins CMO activities, and also initiated the sale of Scil Proteins Production to Wacker Biotech.

16.09.2014 David Veitch has been appointed as Chief Commercial Officer of Basilea Pharmaceutica International Ltd.

© Basilea Pharmaceutica Ltd.

As a member of the management committee, David Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access. Veitch has over 25 years of international commercial experience in the pharmaceutical industry. Before joining Basilea, he led cross-functional organisations at the country and European level and was responsible for the launch of numerous brands across several therapeutic areas. From 1996 ­to 2011, he was President European Operations at Savient Pharmaceuticals. Veitch has also held various positions at Bristol-Myers Squibb UK and Europe. His last position at the company was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, where he led the commercial organisation for the region with a focus on specialty care brands.

15.09.2014 Nektarios Tavernarakis, notable researcher with a focus on cell death, neurodegeneration and aging, has been elected a member of The Academy of Europe (Academia Europaea).

© Academia Europaea

Tavernakis is Research Director at the Institute of Molecular Biology and Biotechnology (IMBB) of the Foundation of Research and technology Hellas (FORTH), and professor at the Medical School of the University of Crete, has been elected a member of the Academy of Europe (Academia Europaea). Tavernarakis’ research focuses on cell death, neurodegeneration and ageing. He has received several notable scientific prizes for his scientific accomplishments. Among his accolades are the Academic Excellence Prize from the Empeirikeion Foundation and the Science Excellence Award, General Secretariat for Research and Technology, Ministry of Education both awarded in Greece in 2012. Before joining IMBB-FORTH as Executive Researcher in 2001, Tavernarakis worked as a Research Associate at Rutgers University, USA. Tavernarakis is also an elected member of EMBO.

04.09.2014 Miriam Monge has been named Director of Marketing for pharma and biotech supplier Sartorius Stedim Biotech’s Integrated Solutions unit.

© Sartorius Stedim Biotech

Monge makes the switch from UK consultancy Biopharm Services where she acted as Vice President of Sales & Marketing. She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice.

02.09.2014 The former Chair of the Supervisory Board of Dutch clinical-stage immunotherapy company ISA Pharmaceuticals B.V., Ronald Loggers will in the future head the company's daily business activities as CEO.

© ISA Pharmaceuticals

Once Managing Director of ISA’s investor Multi­fund B.V., Loggers took over as acting CEO in June. The new Chief Executive, who holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from the Delft University of Technology, has served on boards in the past, and was Managing Director at Pearle Benelux. Prior to that, he worked for McKinsey & Company and Fokker Aircraft.

Vorherige Seite5/25Nächste Seite


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • SYNGENTA430.80 CHF32.0%
  • EVOLVA1.84 CHF20.3%
  • BASILEA132.00 CHF16.7%


  • CYTOS0.66 CHF-32.7%
  • MEDIGENE8.43 EUR-19.3%
  • 4SC4.65 EUR-10.6%


  • WILEX3.95 EUR393.7%
  • FORMYCON28.39 EUR318.7%
  • 4SC4.65 EUR307.9%


  • MOLOGEN5.05 EUR-52.5%
  • PAION2.54 EUR-26.8%
  • BIOFRONTERA2.29 EUR-25.6%

No liability assumed, Date: 28.05.2015

Current issue

All issues